Concerns about the potential of a drug for fatty liver disease cause Intercept to fall.

Published Date: 27 May 2023

The decision by the regulator's advisory panel to postpone an accelerated approval caused worries about the prospects of Intercept's drug to treat a specific form of fatty liver disease, which caused shares of the company to drop by about 16% on Monday.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Does pollution cause cancer?

2.

AI is equally capable of reading breast cancer scans as human radiologists.

3.

EVP Beats Cisplatin for Resectable MIBC

4.

New research points out a promising strategy for treating metastatic medulloblastoma

5.

Academics + Pharma = Big Bucks; New CAR-T Warnings; Patients Seek Cancer Tests.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot